Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis

Inflammatory Bowel Diseases

Volumn 19, Issue 1, 2013, Pages 37-44

  Ananthakrishnan, Ashwin N ^a,b   Korzenik, Joshua R ^a,b   Hur, Chin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Crohn's disease; Infliximab; Mucosal healing

Indexed keywords

INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; REMISSION; RISK FACTOR; SENSITIVITY ANALYSIS; ULCER HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MUCOUS MEMBRANE; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; WOUND HEALING;

EID: 84873724426     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22951     Document Type: Article

References (39)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
2. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
3. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.
4. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct healthcare costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
6. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predictresponse? Am J Gastroenterol. 2011;106:199-212.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
8. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
9. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
10. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
11. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499.
12. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265-274.
13. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a costeffectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520.
14. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: costeffectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76-87.
15. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4: 1017-1024; quiz 976.
16. D'Haens GR, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009;15:1599-1604.
17. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
18. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6:1218-1224.
19. Flynn A, Kane S. Mucosal healing in Crohn's disease and ulcerative colitis: what does it tell us? Curr Opin Gastroenterol. 2011;27:342-345.
20. Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478.
21. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15-29.
22. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastro-intest Endosc. 2006;63:433-442; quiz 464.
23. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56: 453-455.
24. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
25. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-963.
26. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
27. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" inpatients losing response. J Clin Gastroenterol. 2011;45:113-118.
28. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
29. 2010 Drug Topics Red Book. PDR Network, LLC, 2010.
30. Malone DC, Waters HC, Van Den Bos J, et al. A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther. 2010;32:448-458.
31. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000;95:524-530.
32. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a qualityadjusted life year: in search of a standard. Med Decis Making. 2000;20: 332-342.
33. Van Assche G. Does mucosal healing impact patient outcomes long-term? Inflamm Bowel Dis. 2008;14:577-578.
34. af Bjorkesten CG, Nieminen U, Turunen U, et al. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis. 2011;17: 947-953.
35. Colombel JF, Lemann M, Sandborn WJ. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. Gastroenterology. 2010;138:S518.
36. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22:417-430.
37. Bruining DH, Loftus EV Jr, Ehman EC, et al. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9: 679-683 e1.
38. Efthymiou A, Viazis N, Mantzaris G, et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis. 2008;14:1542-1547.
39. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010;102:1238-1252.